Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Operating Income (2019 - 2025)

Historic Operating Income for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$28.8 million.

  • Innate Pharma's Operating Income fell 157.46% to -$28.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$118.1 million, marking a year-over-year decrease of 2297.27%. This contributed to the annual value of -$55.1 million for FY2024, which is 30431.71% down from last year.
  • Latest data reveals that Innate Pharma reported Operating Income of -$28.8 million as of Q2 2025, which was down 157.46% from -$52.9 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Operating Income registered a high of $7.5 million during Q2 2021, and its lowest value of -$59.1 million during Q4 2022.
  • For the 5-year period, Innate Pharma's Operating Income averaged around -$27.8 million, with its median value being -$28.6 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first soared by 18184.34% in 2021, then tumbled by 643822.73% in 2024.
  • Over the past 5 years, Innate Pharma's Operating Income (Quarter) stood at -$52.0 million in 2021, then dropped by 13.69% to -$59.1 million in 2022, then soared by 86.23% to -$8.1 million in 2023, then crashed by 549.05% to -$52.9 million in 2024, then skyrocketed by 45.55% to -$28.8 million in 2025.
  • Its Operating Income was -$28.8 million in Q2 2025, compared to -$52.9 million in Q4 2024 and -$28.3 million in Q2 2024.